Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claude Resil

Internal Medicine Dorchester, MA Medical Doctor

NPI 1639150592 CMS profile 255398

2110 Dorchester Ave, Seton Medical Building, Suite 205, Dorchester, MA 02124

Open in the dashboard

General payments

$24,333

720 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claude Resil of Dorchester, MA is reported in the CMS Open Payments database as having received $24,333 across 720 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,365 87
2024 General $2,929 98
2023 General $8,890 118
2022 General $3,167 113
2021 General $2,711 98
2020 General $1,217 58
2019 General $3,055 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claude Resil
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Claude Resil were reported at $2,365. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Claude Resil Internal Medicine median Middle half National median
2019 $3,055 $159 $48–$570 $163
2020 $1,217 $119 $33–$402 $114
2021 $2,711 $135 $37–$521 $132
2022 $3,167 $141 $42–$496 $149
2023 $8,890 $149 $45–$519 $160
2024 $2,929 $154 $47–$537 $164
2025 $2,365 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $6,823 45 payments
  2. AstraZeneca Pharmaceuticals LP $5,217 172 payments
  3. Novo Nordisk Inc $2,040 82 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,603 67 payments
  5. Esperion Therapeutics, Inc. $1,443 50 payments
  6. Sanofi-Aventis U.S. LLC $1,032 42 payments
  7. Lilly USA, LLC $828 35 payments
  8. Otsuka America Pharmaceutical, Inc. $788 30 payments
  9. Janssen Pharmaceuticals, Inc $645 22 payments
  10. Novartis Pharmaceuticals Corporation $627 35 payments
  11. Other $3,287 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,847 706 payments
  2. Consulting Fee $4,008 1 payment
  3. Travel and Lodging $1,386 4 payments
  4. Education $91 9 payments
Products named General payments · program years 2019–2025
  1. Kerendia $6,823 45 payments
  2. FARXIGA $3,165 89 payments
  3. NEXLETOL $1,443 50 payments
  4. BREZTRI $1,318 40 payments
  5. RYBELSUS $1,219 45 payments
  6. Ozempic $1,060 56 payments
  7. JARDIANCE $1,002 41 payments
  8. REXULTI $771 29 payments
  9. XARELTO $615 20 payments
  10. AIRSUPRA $559 11 payments
  11. Other $9,987 438 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

6,843

Median for Internal Medicine: 777

Drug cost

$808,295

Median for Internal Medicine: $73,373

Branded share of claims

22.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 292 $219,144
Jardiance Empagliflozin Brand 205 $158,437
Januvia Sitagliptin Phosphate Brand 125 $102,289
Trulicity Dulaglutide Brand 66 $83,797
Eliquis Apixaban Brand 71 $50,413
Ozempic Semaglutide Brand 45 $45,189
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 40 $20,402
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 25 $12,454
Namzaric Memantine Hcl/Donepezil Hcl Brand 20 $11,181
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 88 $8,629

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$6,063

Medicare's payments for the services billed

Medicare patients

57

Average age 72

Services billed

134

27 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 40%
Chronic kidney disease 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $718
$718 292 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $277
  • Lilly USA, LLC $116
$394 205 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $331
$331 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $239
  • Lundbeck LLC $71
$310 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

720 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record